About IonTox



IONTOX is a biotechnology company founded in 2014 dedicated to providing expertise to the area of in vitro toxicology, with a mission to build improved methods for predicting human adverse effects from chemical exposure.

From laboratories located in Kalamazoo, Michigan, IONTOX serves a global client base in the pharmaceutical, cosmetic, chemical, tobacco, and food additive industries. Through, consulting, product development, and laboratory services the company contributes to the development, application, and interpretation of alternative testing methods. IONTOX aims to advance current alternative toxicology methods through continuous efforts in the research and development of new in vitro technology. These initiatives have led to the development of IONTOX’s  Human Dynamic Multiple Organ Plate (HuDMOP).

DMOP is a meso-scale multiple organ culture plate linked with micro-fluidics that has the capability to provide key information on a compound’s systemic toxicity. IONTOX has worked with Scientists Melvin E. Anderson, Harvey J. Clewell III, and Miyoung Yoon of ScitoVation (formerly known has the Hammer Institute) to develop pharmacokinetic models based on the data collected from HuDMOP. A key objective, from IONTOX’s collaboration with ScitoVation, is to develop scaling factors that can be used to translate in vitro pharmacokinetics in the plate to humans. Ultimately, when combined with markers of cell health DMOP will provide compound data for absorption, distribution, metabolism, and toxicity in humans.

Through the company’s three branches, Consulting, New Products, and Laboratory Services IONTOX offers Advanced in vitro solutions that promise to increase the reliability of in vitro toxicology. This in-turn will reduce animal usage, improve the success of new drug candidates, and provide an advanced method of understanding systemic toxicity. If you are interested in discussing how IONTOX expertise can help you; please contact us at 269.372.3395 and an IONTOX scientist will answer your query promptly.